Bank of America CEO Brian Moynihan revealed the company spends over $250 million annually on GLP-1 weight loss medications for its 211,000 employees, a cost that has risen from zero five years ago. This expense now accounts for about 13% of the bank's total $2 billion healthcare budget. Moynihan considers this a valuable investment due to the potential health benefits, including reduced cardiovascular risks and improved employee well-being. The bank also negotiates drug prices aggressively and pairs medication access with health coaching to maximize benefits.
Bank of America announced it will redeem all outstanding Floating Rate Senior Notes ($500 million) and Fixed/Floating Rate Senior Notes ($1.5 billion), both due September 2027, on September 15, 2026. The redemption price will be 100% of the principal...
Bank of America announced it will redeem all outstanding CAD425 million Floating Rate Senior Notes and CAD1 billion Fixed/Floating Rate Senior Notes due September 2027 on September 15, 2026. The redemption will be at 100% of principal plus accrued in...
BacTech Environmental has initiated a project in Peru through its subsidiary BacTech Verde Peru S.A.C. to explore reprocessing historic mine tailings using its bioleaching technology, aiming to recover gold, silver, and copper. The company is reviewi...
Nvidia's stock has risen nearly 6% in the past month due to strong demand in the AI sector. Analyst Aksel Kibar predicts a rally to $235, close to Nvidia's previous all-time high, based on technical patterns and support from the 200-day moving averag...
Goldman Sachs analyzed $10 trillion in equity holdings and found that both hedge funds and mutual funds share strong interest in four large-cap dividend-paying financial stocks: Bank of America, Capital One Financial, Mastercard, and Visa. These comp...
